Citations

Clear

246 citation(s) found for "Study, Alfa".

Plasma amyloid β levels are driven by genetic variants near APOE, BACE1, APP, PSEN2 : A genome‐wide association study in over 12,000 non‐demented participants
Grenier‐Boley, Benjamin , Simino, Jeannette , Adams, Hieab H.H. , White, Charles C. , Terzikhan, Natalie, Cruchaga, Carlos , Knol, Maria J. , Li, Shuo , Schraen, Susanna, Grove, Megan L. , Satizábal, Claudia L. , Amin, Najaf , Younkin, Steven G., Initiative, Alzheimer's Disease Neuroimaging, Gottesman, Rebecca F., Buée, Luc , Uitterlinden, André G. , DeCarli, Charles , Bressler, Jan , DeStefano, Anita L. , Dartigues, Jean‐François, Boerwinkle, Eric , Tzourio, Christophe , Fornage, Myriam , Jager, Phil De, Reitz, Christiane, Mosley, Thomas H. , Lambert, Jean‐Charles , Duijn, Cornelia M. van , DeCarli, Charles , Younkin, Steven, Cruchaga, Carlos , Adams, Hieab H H , Satizabal, Claudia L , Tzourio, Christophe , van Duijn, Cornelia M , Damotte, Vincent , Lee, Sven J. van der , Chouraki, Vincent Antoine , Tosto, Giuseppe , Berr, Claudine , Initiative, Alzheimer's Disease Neuroimaging, Beiser, Alexa , Knopman, David S. , Yang, Qiong , Ikram, M. Arfan , Amouyel, Philippe , Jager, Philip L. De , Seshadri, Sudha

Mayo Clinic

Alzheimer's & Dementia | May 18, 2021 | Volume: 17 | Issue: 10 | Pages: 1663-1674

10.1002/alz.12333 | PMID 34002480 Get It

Abstract Introduction There is increasing interest in plasma amyloid beta (Aβ) as an endophenotype of Alzheimer's disease (AD). Identifying the genetic determinants of plasma Aβ levels may elucidate important biological processes that determine plasma Aβ measures. Methods We included 12,369 non‐demented participants from eight population‐based studies. Imputed genetic data and measured plasma Aβ1‐40, Aβ1‐42 levels and Aβ1‐42/Aβ1‐40 ratio were used to perform genome‐wide association studies, and gene‐based and pathway analyses. Significant variants and genes were followed up for their association with brain positron emission tomography Aβ deposition and AD risk. Results Single‐variant analysis identified associations with apolipoprotein E ( APOE ) for Aβ1‐42 and Aβ1‐42/Aβ1‐40 ratio, and BACE1 for Aβ1‐40. Gene‐based analysis of Aβ1‐40 additionally identified associations for APP , PSEN2 , CCK , and ZNF397 . There was suggestive evidence for interaction between a BACE1 variant and APOE ε4 on brain Aβ deposition. Discussion Identification of variants near/in known major Aβ‐processing genes strengthens the relevance of plasma‐Aβ levels as an endophenotype of AD.
Symptom-specific differential motor network modulation by deep brain stimulation in Parkinson’s disease
Gibson, William S. , Rusheen, Aaron E. , In, Myung‐Ho, Gorny, Krzysztof R. , Felmlee, Joel P. , Klassen, Bryan T. , Jung, Sung Jun , Min, Hoon‐Ki , Lee, Kendall H. , In, Myung‐Ho , Min, Hoon-Ki Paul , In, Myung-Ho , Gibson, William S., Oh, Yoonbae , Jo, Hang Joon

Mayo Clinic

Journal of Neurosurgery | May 14, 2021 | Volume: 135 | Issue: 6 | Pages: 1771-1779

10.3171/2020.10.jns202277 | PMID 33990083 Get It

OBJECTIVE Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is an established neurosurgical treatment for the motor symptoms of Parkinson’s disease (PD). While often highly effective, DBS does not always yield optimal therapeutic outcomes, and stimulation-induced adverse effects, including paresthesia, muscle contractions, and nausea/lightheadedness, commonly occur and can limit the efficacy of stimulation. Currently, objective metrics do not exist for monitoring neural changes associated with stimulation-induced therapeutic and adverse effects. METHODS In the present study, the authors combined intraoperative functional MRI (fMRI) with STN DBS in 20 patients with PD to test the hypothesis that stimulation-induced blood oxygen level–dependent signals contained predictive information concerning the therapeutic and adverse effects of stimulation. RESULTS As expected, DBS resulted in blood oxygen level–dependent activation in myriad motor regions, including the primary motor cortex, caudate, putamen, thalamus, midbrain, and cerebellum. Across the patients, DBS-induced improvements in contralateral Unified Parkinson’s Disease Rating Scale tremor subscores correlated with activation of thalamic, brainstem, and cerebellar regions. In addition, improvements in rigidity and bradykinesia subscores correlated with activation of the primary motor cortex. Finally, activation of specific sensorimotor-related subregions correlated with the presence of DBS-induced adverse effects, including paresthesia and nausea (cerebellar cortex, sensorimotor cortex) and unwanted muscle contractions (caudate and putamen). CONCLUSIONS These results suggest that DBS-induced activation patterns revealed by fMRI contain predictive information with respect to the therapeutic and adverse effects of DBS. The use of fMRI in combination with DBS therefore may hold translational potential to guide and improve clinical stimulator optimization in patients.
Longitudinal CSF proteomics identifies NPTX2 as a prognostic biomarker of Alzheimer's disease
Libiger, Ondrej , Shaw, Leslie M. , Watson, Mark H., Umaña, Kelly L., Biarnes, Michael C., Canet‐Avilés, Rosa M., Breton, Yannick‐André, Cortes, Laetitia, Chelsky, Daniel , Spellman, Daniel S. , Baker, Susan , Raghavan, Nandini, Potter, William Z., (ADNI), Alzheimer's Disease Neuroimaging Initiative, Rosenbaugh, Erin G. , Nairn, Angus C. , Canet-Aviles, Rosa, Jack, Clifford R. , (ADNI), Alzheimer's Disease Neuroimaging Initiative

Mayo Clinic

Alzheimer's & Dementia | May 13, 2021 | Volume: 17 | Issue: 12 | Pages: 1976-1987

10.1002/alz.12353 | PMID 33984181 Get It

Abstract Introduction: Biomarkers that reflect pathologic processes affecting neuronal function during preclinical and early stages of Alzheimer's disease (AD) are needed to aid drug development. Methods: A targeted, stable isotope, quantitative mass spectrometry‐based investigation of longitudinal changes in concentrations of previously identified candidate biomarkers was performed in cerebrospinal fluid (CSF) of Alzheimer's Disease Neuroimaging Initiative participants who were classified as cognitively normal (CN; n = 76) or with mild cognitive impairment (MCI; n = 111) at baseline. Results: Of the candidate biomarkers, the CSF concentration of neuronal pentraxin 2 (NPTX2), a protein involved in synaptic function, exhibited rates of change that were significantly different between three comparison groups (i.e., CN vs. MCI participants; AD pathology positive vs. negative defined by phosphorylated tau181/amyloid beta1‐42 ratio; and clinical progressors vs. non‐progressors). The rate of change of NPTX2 also significantly correlated with declining cognition. Discussion: CSF NPTX2 concentration is a strong prognostic biomarker candidate of accelerated cognitive decline with potential use as a therapeutic target.
The Second NINDS/NIBIB Consensus Meeting to Define Neuropathological Criteria for the Diagnosis of Chronic Traumatic Encephalopathy
Bieniek, Kevin F. , Cairns, Nigel J. , Crary, John F. , Folkerth, Rebecca D., Keene, C. Dirk , Perl, Daniel P. , Stein, Thor D. , Vonsattel, Jean‐Paul, Stewart, William , Gordon, Wayne A., Alvarez, Victor E., Alosco, Michael L. , McKee, Ann C. , Babcock, Debra, Bellgowan, Patrick S.F. , Crane, Paul K. , Edlow, Brian L. , Huber, Bertrand R., Kiernan, Patrick T. , Dickson, Dennis W. , Litvan, Irene , Dams-O’Connor, Kristen , Tripodis, Yorghos , Mez, Jesse , Huber, Bertrand R. , Koroshetz, Walter J.

Mayo Clinic

Journal of Neuropathology & Experimental Neurology | February 21, 2021 | Volume: 80 | Issue: 3 | Pages: 210-219

10.1093/jnen/nlab001 | PMID 33611507 Get It

Abstract Chronic traumatic encephalopathy (CTE) is a neurodegenerative disorder associated with exposure to head trauma. In 2015, a panel of neuropathologists funded by the NINDS/NIBIB defined preliminary consensus neuropathological criteria for CTE, including the pathognomonic lesion of CTE as “an accumulation of abnormal hyperphosphorylated tau (p-tau) in neurons and astroglia distributed around small blood vessels at the depths of cortical sulci and in an irregular pattern,” based on review of 25 tauopathy cases. In 2016, the consensus panel met again to review and refine the preliminary criteria, with consideration around the minimum threshold for diagnosis and the reproducibility of a proposed pathological staging scheme. Eight neuropathologists evaluated 27 cases of tauopathies (17 CTE cases), blinded to clinical and demographic information. Generalized estimating equation analyses showed a statistically significant association between the raters and CTE diagnosis for both the blinded (OR = 72.11, 95% CI = 19.5–267.0) and unblinded rounds (OR = 256.91, 95% CI = 63.6–1558.6). Based on the challenges in assigning CTE stage, the panel proposed a working protocol including a minimum threshold for CTE diagnosis and an algorithm for the assessment of CTE severity as “Low CTE” or “High CTE” for use in future clinical, pathological, and molecular studies.
Initial testing of pegfilgrastim (Neulasta Onpro) on‐body injector in multiple radiological imaging environments
Long, Zaiyang , Kurup, A. Nicholas , Jensen, Nicole M., Hangiandreou, Nicholas J., Schueler, Beth A. , Yu, Lifeng , Wood, Christopher P. , Felmlee, Joel P. , Kurup, Anil Nicholas, Kurup, Anil N , Yu, Lifeng , Leng, Shuai

Mayo Clinic

Journal of Applied Clinical Medical Physics | January 4, 2021 | Volume: 22 | Issue: 1 | Pages: 343-349

10.1002/acm2.13156 | PMID 33395503 Get It

AbstractPurposeAn increasing number of implantable or external devices can impact whether patients can receive radiological imaging examinations. This study examines and tests the Neulasta (pegfilgrastim) Onpro on‐body injector in multiple imaging environments.MethodsThe injector was analyzed for four imaging modalities with testing protocols and strategies developed for each modality. In x‐ray and computed tomography (CT), scans with much higher exposure than clinical protocols were performed with the device attached to an anthropomorphic phantom. The device was monitored until the completion of drug delivery. For magnetic resonance imaging (MRI), the device was assessed using a hand‐held magnet and underwent the magnetically induced displacement testing in a 1.5T clinical MRI scanner room. For ultrasound, magnetic field changes were measured around an ultrasound scanner system with three transducers.ResultsFor x‐ray and CT no sign of device error was identified during or after the high radiation exposure scans. Drug delivery was completed at expected timing with expected volume. For MRI the device showed significant attractive force towards the hand‐held magnet and a 50‐degree deflection angle at 50 cm from the opening of the scanner bore. No further assessment from the gradient or radiofrequency field was deemed necessary. For ultrasound the maximum magnetic field change from baseline was measured to be +11.7 μT in comparison to +74.2 μT at 4 inches from a working microwave.ConclusionsNo device performance issue was identified under the extreme test conditions in x‐ray or CT. The device was found to be MR Unsafe. Magnetic field changes around an ultrasound system met the limitation set by manufacture. Patient ultrasound scanning is considered safe as long as the transducers do not inadvertently loosen the device.
Early Selective Vulnerability of the CA2 Hippocampal Subfield in Primary Age-Related Tauopathy
Walker, Jamie M. , Richardson, Timothy E. , Iida, Megan A., Foong, Chan, Shang, Ping , Attems, Johannes , Ayalon, Gai , Beach, Thomas G. , Bigio, Eileen H. , Budson, Andrew E. , Cairns, Nigel J. , Corrada, María M. , Cortés, Etty , Flanagan, Margaret E. , Franklin, Erin , Gearing, Marla , Glass, Jonathan D. , Hansen, Lawrence A. , Haroutunian, Vahram , Kawas, Claudia H. , Keene, C. Dirk , Kofler, Julia , Kovács, Gábor G. , Lee, Edward B. , Lutz, Mirjam I. , Masliah, Eliezer , McKee, Ann C. , Mesulam, M.‐Marsel, Nelson, Peter T. , Perrin, Richard J. , Pham, Thao, Purohit, Dushyant P. , Sakai, Kenji , Sano, Mary , Stein, Thor D. , Teich, Andrew F. , Trojanowski, John Q. , Troncoso, Juan C. , Vonsattel, Jean-Paul G., Weıntraub, Sandra , Woltjer, Randall L. , Yamada, Masahito , Yu, Lei , Crary, John F. , Seshadri, Sudha , Murray, Melissa, Seshadri, Sudha , Kovacs, Gabor G , Murray, Melissa E , Teich, Andrew F , Lee, Edward B , Farrell, Kurt , Dickson, Dennis W. , Fischer, Peter A. , Hof, Patrick R. , Honig, Lawrence S. , Mao, Qinwen , McMillan, Corey T. , Murray, Melissa E. , Poon, Wayne W. , Rissman, Robert A. , Schneider, Julie A. , Wolk, David A. , White, Charles L. , Flanagan, Margaret E

Mayo Clinic

Journal of Neuropathology & Experimental Neurology | December 23, 2020 | Volume: 80 | Issue: 2 | Pages: 102-111

10.1093/jnen/nlaa153 | PMID 33367843 Get It

Abstract Primary age-related tauopathy (PART) is a neurodegenerative entity defined as Alzheimer-type neurofibrillary degeneration primarily affecting the medial temporal lobe with minimal to absent amyloid-β (Aβ) plaque deposition. The extent to which PART can be differentiated pathoanatomically from Alzheimer disease (AD) is unclear. Here, we examined the regional distribution of tau pathology in a large cohort of postmortem brains (n = 914). We found an early vulnerability of the CA2 subregion of the hippocampus to neurofibrillary degeneration in PART, and semiquantitative assessment of neurofibrillary degeneration in CA2 was significantly greater than in CA1 in PART. In contrast, subjects harboring intermediate-to-high AD neuropathologic change (ADNC) displayed relative sparing of CA2 until later stages of their disease course. In addition, the CA2/CA1 ratio of neurofibrillary degeneration in PART was significantly higher than in subjects with intermediate-to-high ADNC burden. Furthermore, the distribution of tau pathology in PART diverges from the Braak NFT staging system and Braak stage does not correlate with cognitive function in PART as it does in individuals with intermediate-to-high ADNC. These findings highlight the need for a better understanding of the contribution of PART to cognitive impairment and how neurofibrillary degeneration interacts with Aβ pathology in AD and PART.
7T MR Thermometry technique for validation of system‐predicted SAR with a home‐built radiofrequency wrist coil
Fagan, Andrew , Jacobs, Paul , Hulshizer, Thomas C., Rossman, Phillip J. , Frick, Matthew A., Amrami, Kimberly K. , Felmlee, Joel P. , Jacobs, Paul S, Fagan, Andrew J

Mayo Clinic

Medical Physics | December 10, 2020 | Volume: 48 | Issue: 2 | Pages: 781-790

10.1002/mp.14641 | PMID 33294999 Get It

PurposeA 7T magnetic resonance thermometry (MRT) technique was developed to validate the conversion factor between the system‐measured transmitted radiofrequency (RF) power into a home‐built RF wrist coil with the system‐predicted SAR value. The conversion factor for a new RF coil developed for ultra high magnetic field MRI systems is used to ensure that regulatory limits on RF energy deposition in tissue, specifically the local 10g‐averaged specific absorption rate (SAR10g), are not exceeded. MRT can be used to validate this factor by ensuring that MRT‐measured SAR values do not exceed those predicted by the system.MethodsA 14‐cm diameter high‐pass birdcage RF coil was built to image the wrist at 7T. A high spatial and temporal resolution dual‐echo gradient echo MRT technique, incorporating quasi‐simultaneous RF‐induced heating and temperature change measurements using the proton resonance frequency method, was developed. The technique allowed for high‐temperature resolution measurements (~±0.1°C) to be performed every 20 s over a 4‐min heating period, with high spatial resolution (2.56 mm3 voxel size) and avoiding phase discontinuities arising from severe magnetic susceptibility‐induced B0 inhomogeneities. Magnetic resonance thermometry was performed on a phantom made from polyvinylpyrrolidone to mimic the dielectric properties of muscle tissue at 297.2 MHz. Temperature changes measured with MRT and four fiber optic temperature sensors embedded in the phantom were compared. Electromagnetic simulations of the coil and phantom were developed and validated via comparison of simulated and measured B1+ maps in the phantom. The position of maximum SAR within the coil was determined from simulations, and MRT was performed within a wrist‐sized piece of meat positioned at that SAR hotspot location. MRT‐measured and system‐predicted SAR values for the phantom and meat were compared.ResultsTemperature change measurements from MRT matched closely to those from the fiber optic temperature sensors. The simulations were validated via close correlation between the simulated and MRT‐measured B1+ and SAR maps. Using a coil conversion factor of 2 kg−1, MRT‐measured point‐SAR values did not exceed the system‐predicted SAR10g in either the uniform phantom or in the piece of meat mimicking the wrist located at the SAR hotspot location.ConclusionsA highly accurate MRT technique with high spatial and temporal resolution was developed. This technique can be used to ensure that system‐predicted SAR values are not exceeded in practice, thereby providing independent validation of SAR levels delivered by a newly built RF wrist coil. The MRT technique is readily generalizable to perform safety evaluations for other RF coils at 7T.
Identification of NPTX2 as a prognostic biomarker of Alzheimer’s disease through a longitudinal CSF proteomics study in ADNI subjects
Libiger, Ondrej , Shaw, Leslie M. , Watson, Mark H., Umaña, Kelly L., Canet‐Avilés, Rosa M., Breton, Yannick‐André, Cortes, Laetitia, Chelsky, Daniel , Spellman, Daniel S. , Baker, Susan , Raghavan, Nandini, Potter, William Z., Nairn, Angus C. , Canet-Aviles, Rosa, Jack, Clifford R.

Mayo Clinic

Alzheimer's & Dementia | December 7, 2020 | Volume: 16 | Issue: S5 | Pages: No page available

10.1002/alz.047605 Get It

AbstractBackgroundMany biomarkers have been identified which are relevant to studies of Alzheimer’s disease (AD), especially pertaining to the evolution of amyloid plaque, tau tangle pathology and loss of brain tissue. There remains, however, the need for additional biomarkers that reflect pathologic processes affecting neuronal function during pre‐clinical and prodromal stages, to help accelerate drug development efforts.MethodA retrospective investigation of longitudinal changes in concentrations of five analytes (CgA, NPTX2, VGF, SCG2, FABP3) was performed in CSF of ADNI subjects. Rates of longitudinal change in these candidate proteins were compared between: a) Cognitively normal subjects (CN; n = 76) versus subjects with mild cognitive impairment (MCI; n = 111) at baseline; b) Subjects categorized as p‐Tau181/Aβ1‐42 ratio positive versus negative at baseline; and c) ‘Progressors’, i.e., subjects who progressed from CN to MCI or MCI to Dementia within a predefined period versus subjects categorized as ‘non‐progressors’. Following a pre‐specified analysis plan involving mixed‐effects linear models adjusting for relevant covariates, the association between changes in each analyte’s concentration and subjects’ clinical progression was quantified.ResultNPTX2, a protein involved in synaptic function, showed the strongest association with baseline clinical diagnosis of MCI, and a positive p‐Tau181/Aβ1‐42 ratio – the biomarker profile indicative of AD. Differences in the rates of decline in NPTX2 concentration between subjects classified as CN and MCI as well as between p‐Tau181/Aβ1‐42 ratio positive and negative subjects were highly significant (p=0.008 and p<0.0001 resp.), suggesting a complex interaction between the rate of decline in subjects at various stages along the disease continuum. Of the five analytes, only the rates of change in NPTX2 concentrations differed between progressors and non‐progressors (mean difference: 0.08 ± 0.02 ng/mL/year); p = 0.0004), further validating the association of changes in NPTX2 concentration and clinical prognosis. Additional exploratory analyses indicated the presence of a correlation between NPTX2 rates of change and declining cognition measured by MMSE (coef. = 0.3, p = 0.02), and Adas‐Cog 13 (coef. = ‐0.3, p = 0.01).ConclusionThese results suggest that NPTX2 concentration may serve as a prognostic biomarker of accelerated cognitive decline in at least a subset of individuals with AD.
High-Sensitivity C-Reactive Protein is a Prognostic Biomarker of Six-Month Disability after Traumatic Brain Injury: Results from the TRACK-TBI Study
Xu, Linda , Yue, John K. , Korley, Frederick K. , Puccio, Ava M. , Yuh, Esther L. , Sun, Xiaoying, Rabinowitz, Miri, Vassar, Mary J. , Taylor, Sabrina R. , Winkler, Ethan A. , Puffer, Ross C. , Deng, Hansen , McCrea, Michael , Robertson, Claudia S. , Levin, Harvey S. , Dikmen, Sureyya, Okonkwo, David O. , Jain, Sonia , Manley, Geoffrey T. , Investigators, The TRACK-TBI, Boase, Kim, Bodien, Yelena, Bullock, M. Ross, Crawford, Karen, Duhaime, Ann-Christine, Ellenbogen, Richard, Feeser, V. Ramana, Ferguson, Adam R., Gaudette, Etienne, González, Luis, Gopinath, Shankar, Gullapalli, Rao, Hemphill, J. Claude, Hotz, Gillian , Kramer, Joel H. , Kreitzer, Natalie, Lindsell, Chris, Machamer, Joan , Madden, Christopher , McAllister, Thomas W. , Merchant, Randall, Noël, Florence, Palacios, Eva , Perl, Daniel, Rosand, Jonathan, Satris, Gabriella, Seabury, Seth, Toga, Arthur W. , Adeoye, Alex VaOpeolu, Bodien, Yelena, Bullock, M. Ross, Crawford, Karen, Ferguson, Adam R., Gaudette, Etienne, Gullapalli, Rao, Hemphill, J. Claude, Kreitzer, Natalie, Lindsell, Chris, Merchant, Randall, Perl, Daniel, Rosand, Jonathan, Seabury, Seth, Valadka, Alex B. , Vespa, Paul , Zafonte, Ross , Hemphill, J. Claude , Ferguson, Adam R. , Kreitzer, Natalie , Stein, Murray B. , Temkin, Nancy R. , Giacino, Joseph T. , Mukherjee, Pratik , Wang, Kevin , Markowitz, Amy J. , Diaz‐Arrastia, Ramon , Investigators, The TRACK-TBI, Adeoye, Opeolu M , Badjatia, Neeraj , Bodien, Yelena, Bullock, M. Ross, Chesnut, Randall Matthew , Corrigan, John D. , Crawford, Karen, Ferguson, Adam R., Foreman, Brandon , Gardner, Raquel C. , Gaudette, Etienne, Goldman, Dana P. , Gopinath, Shankar P. , Gullapalli, Rao, Hemphill, J. Claude, Kreitzer, Natalie, Lindsell, Chris, Martin, Alastair J. , Merchant, Randall, Nelson, Lindsay D. , Ngwenya, Laura Benjamin , Perl, Daniel, Rosand, Jonathan, Sander, Angelle M. , Schnyer, David M. , Seabury, Seth, Bodien, Yelena, Bullock, M. Ross, Crawford, Karen, Ferguson, Adam R., Gaudette, Etienne, Gullapalli, Rao, Hemphill, J. Claude, Kreitzer, Natalie, Lindsell, Chris, Merchant, Randall, Perl, Daniel, Rosand, Jonathan, Seabury, Seth

Mayo Clinic

Journal of Neurotrauma | November 9, 2020 | Volume: 38 | Issue: 7 | Pages: 918-927

10.1089/neu.2020.7177 | PMID 33161875 Get It

Feed-forward, feed-back, and distributed feature representation during visual word recognition revealed by human intracranial neurophysiology
Long, Laura, Yang, Minda, Kriegeskorte, Nikolaus , Jacobs, Joshua , Sperling, Michael R. , Sharan, Ashwini , Burks, Alexis, Gross, Robert A. , Sheth, Sameer A. , Gorniak, Richard , Wanda, Paul A., Kahana, Michael J. , Mesgarani, Nima , Sperling, Michael R , Long, Laura, Remez, Robert E. , Lega, Bradley Charles , Burks, Alexis, Worrell, Gregory A. , Jobst, Barbara C. , Davis, Kathryn A. , Zaghloul, Kareem A. , Stein, Joel M. , Das, Sandhitsu R.

Mayo Clinic

No container title available | October 26, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-95141/v1 Get It

Abstract Scientists debate where, when, and how different visual, orthographic, lexical, and semantic features are involved in visual word recognition. In this study, we investigate intracranial neurophysiology data from 151 patients engaged in reading single words. Using representational similarity analysis, we characterize the neural representation of a hierarchy of word features across the entire cerebral cortex. We find evidence of both feed-forward and feedback processing, with early representation of visual and lexical information in lingual gyrus followed by lexical representation in fusiform gyrus and semantic sensitivity in inferior frontal gyrus, with letter representation emerging later in fusiform gyrus. Furthermore, we observed a variety of anatomically heterogeneous temporal response shapes, and these functional populations had significant feature sensitivity. Taken together, our results demonstrate the early influence of lexical, phonological, and semantic features in visual word recognition and reveal feed-forward, feed-back, and anatomically distributed processing mechanisms that contribute to visual word recognition.